ClinicalTrials.gg
CompletedNCT00876343Updated Feb 10, 2014Results posted

Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

A Phase 3 interventional study of Aripiprazole (Fixed dose) and Aripiprazole (Titrated dose) in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2014-02-10.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 33 studies testing aripiprazole in Depressive Disorder, Major — 2 open to participants now, 2 under way, none of them phase 3. Aripiprazole · Depressive Disorder, Major.

Enrollment
6th of 33
586 · median 173
Started
2009
with 2 others
Phase 3
13 of 33
none open now
Registered
10th of 33
by date
Lead sponsor
2 of 33
Otsuka Pharmaceutical Co., Ltd.

Among the 33 studies testing aripiprazole in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 10th registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 33 studies testing aripiprazole in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing aripiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy co-administered with either an selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) in patients with major depressive disorder.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are either inpatients or outpatients
  2. Patients who have the ability to understand and to provide to the examination, observation, and evaluation processes specified in this protocol, and have signed the informed consent form based on a full understanding of the trial
  3. Patients diagnosed as having either "296.2x Major Depressive Disorder, Single Episode" or "296.3x Major Depressive Disorder, Recurrent" according to , and for whom the current episode of major depressive disorder has been ongoing for more than 8 weeks
  4. Patients with a HAM-D17 total score of 18 or more

Exclusion criteria

Exclusion Criteria:

  1. Female patients of child bearing potential who wish to become pregnant during the treatment period, or within 4 weeks after study completion/discontinuation
  2. Female patients who are pregnant, possibly pregnant, or breast feeding
  3. Patients judged to be unable to tolerate any type of antidpressant treatment (including drugs not being used in the current episode of major depressive disorder), based on treatment history to date
  4. Patients who have previously received electro-convulsive therapy
  5. Patients who have participated in clinical studies on medical devices or other drugs within the past month
  6. Patients at risk of having serious adverse events or developing symptoms that could interfere with safety and efficacy evaluations (such as symptoms of fibromyalgia syndrome overlapping with symptoms of depression), based on previous medical history
  7. Patients with a history or a complication of diabetes
  8. Patients with thyroid disease (excluding patients who are stabilized on drug therapy for at least 3 months)
  9. Patients with a history of serotonin syndrome or psychotropic neuroleptic malignant syndrome
  10. Patients with a history of seizure disorder (epilepsy etc.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
586 participants (actual)

Study arms

  • Experimental
    1

    Fixed dose

    Drug: Aripiprazole (Fixed dose)

  • Experimental
    2

    Titration dose

    Drug: Aripiprazole (Titrated dose)

  • Placebo comparator
    3

    Placebo

    Drug: Placebo

Interventions

  • DrugAripiprazoleStudies of AripiprazoleAripiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    administered orally once daily, 3 mg daily, 6 weeks

    Also known as: Aripiprazole

  • DrugAripiprazoleStudies of AripiprazoleAripiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    administered orally once daily, 3 to 15 mg daily, 6 weeks

    Also known as: Aripiprazole

  • DrugPlacebo

    administered orally once daily, 6 weeks

    Also known as: Placebo of aripiprazole

06

What researchers measure

Primary outcomes

  1. Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The change in MADRS total score from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period by covariance analysis, and compared the aripiprazole variable dose group with the placebo group as well as the aripiprazole fixed dose group with the placebo group. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts

    Time frame: Baseline (the end of the SSRI/SNRI treatment period), at completion of administration

Secondary outcomes

  1. MADRS Response Rate

    The percentage of subjects with a decrease in MADRS total score of 50% or more, from the end of the SSRI/SNRI treatment period to the end of the placebo-controlled, double-blind treatment period (or withdrawal).

    Time frame: Baseline (the end of the SSRI/SNRI treatment period), at completion of administration

  2. Mean Change in Sheehan Disability Scale (SDISS)

    The endpoint evaluated the change in SDISS from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period. The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).

    Time frame: Baseline (the end of the SSRI/SNRI treatment period), at completion of administration

07

Results

Posted Feb 10, 2014

Participant flow

Participant flow — Overall Study
MilestoneVariable Dose Group of AripiprazoleFixed Dose Group of AripiprazolePlacebo Group
Started194197195
Completed177180183
Not completed171712
Withdrew: Adverse event782
Withdrew: Withdrawal by subject443
Withdrew: Lack of efficacy001
Withdrew: Protocol violation411
Withdrew: Physician decision011
Withdrew: Diabetic glucose level or hba1c>=6.5%011
Withdrew: Change of residence or other commitments223

Outcome measures

PrimaryMean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The change in MADRS total score from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period by covariance analysis, and compared the aripiprazole variable dose group with the placebo group as well as the aripiprazole fixed dose group with the placebo group. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts

Time frame:
Baseline (the end of the SSRI/SNRI treatment period), at completion of administration
Reported as:
Mean · Rating score
Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Rating scoreVariable Dose Group of AripiprazoleFixed Dose Group of AripiprazolePlacebo Group
Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-9.6 ± 0.6-10.5 ± 0.6-7.4 ± 0.6
Statistical analysis
  • Variable Dose Group of Aripiprazole vs Placebo Group · ANCOVA · p = 0.006 · Mean difference (final values): -2.2 · 95% CI -3.7 to -0.6
  • Fixed Dose Group of Aripiprazole vs Placebo Group · ANCOVA · p = <0.001 · Mean difference (final values): -3.1 · 95% CI -4.6 to -1.5
SecondaryMADRS Response Rate

The percentage of subjects with a decrease in MADRS total score of 50% or more, from the end of the SSRI/SNRI treatment period to the end of the placebo-controlled, double-blind treatment period (or withdrawal).

Time frame:
Baseline (the end of the SSRI/SNRI treatment period), at completion of administration
Reported as:
Number · percentage of subjects
MADRS Response Rate
percentage of subjectsVariable Dose Group of AripiprazoleFixed Dose Group of AripiprazolePlacebo Group
MADRS Response Rate39.242.128.2
SecondaryMean Change in Sheehan Disability Scale (SDISS)

The endpoint evaluated the change in SDISS from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period. The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).

Time frame:
Baseline (the end of the SSRI/SNRI treatment period), at completion of administration
Reported as:
Mean · Rating score
Mean Change in Sheehan Disability Scale (SDISS)
Rating scoreVariable Dose Group of AripiprazoleFixed Dose Group of AripiprazolePlacebo Group
Mean Change in Sheehan Disability Scale (SDISS)-1.03 ± 0.11-0.96 ± 0.11-0.46 ± 0.11

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Variable Dose Group of Aripiprazole—3/194 (1.5%)140/194 (72.2%)
Fixed Dose Group of Aripiprazole—2/197 (1%)122/197 (61.9%)
Placebo Group—2/195 (1%)92/195 (47.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventVariable Dose Group of AripiprazoleFixed Dose Group of AripiprazolePlacebo Group
Malignant MelanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1940/1970/195
Major DepressionPsychiatric disorders1/1940/1970/195
Suicide AttemptPsychiatric disorders1/1941/1971/195
ContusionInjury, poisoning and procedural complications0/1940/1971/195
Head InjuryInjury, poisoning and procedural complications0/1940/1971/195
Ligament SprainInjury, poisoning and procedural complications0/1940/1971/195
Post-Traumatic Neck SyndromeInjury, poisoning and procedural complications0/1940/1971/195
Traffic AccidentInjury, poisoning and procedural complications0/1940/1971/195
Haemorrhage SubcutaneousSkin and subcutaneous tissue disorders0/1940/1971/195
Back PainMusculoskeletal and connective tissue disorders0/1941/1970/195
Most frequent other events
Showing 10 of 33
Most frequent other events
EventVariable Dose Group of AripiprazoleFixed Dose Group of AripiprazolePlacebo Group
AkathisiaNervous system disorders71/19428/1978/195
NasopharyngitisInfections and infestations31/19430/19728/195
TremorNervous system disorders20/19414/1975/195
SomnolenceNervous system disorders15/19419/19713/195
ConstipationGastrointestinal disorders15/1947/1974/195
HeadacheNervous system disorders4/1949/19715/195
Alanine Aminotransferase IncreasedInvestigations13/19414/1973/195
ThirstGeneral disorders13/19410/1973/195
Weight IncreasedInvestigations12/1948/1971/195
MalaiseGeneral disorders10/1942/1978/195

Baseline characteristics

Age, Continuous
Age, Continuous(years)Variable Dose Group of AripiprazoleFixed Dose Group of AripiprazolePlacebo GroupTotal
Mean38.1 ± 9.639.2 ± 9.138.7 ± 9.238.7 ± 9.3
Age, Categorical
Age, Categorical(Participants)Variable Dose Group of AripiprazoleFixed Dose Group of AripiprazolePlacebo GroupTotal
<=18 years0000
Between 18 and 65 years194197195586
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Variable Dose Group of AripiprazoleFixed Dose Group of AripiprazolePlacebo GroupTotal
Female937380246
Male101124115340
Region of Enrollment
Region of Enrollment(participants)Variable Dose Group of AripiprazoleFixed Dose Group of AripiprazolePlacebo GroupTotal
Japan194197195586
08

Study locations

8 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Hokkaido Region, Japan
  • Kanto region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

References and documents

Publications

  • Ozaki N, Otsubo T, Kato M, Higuchi T, Ono H, Kamijima K; ADMIRE Study Group. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. Psychiatry Clin Neurosci. 2015 Jan;69(1):34-42. doi: 10.1111/pcn.12214. Epub 2014 Aug 4. PubMed 24965202 ↗
  • Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T; ADMIRE Study Group. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord. 2013 Dec;151(3):899-905. doi: 10.1016/j.jad.2013.07.035. Epub 2013 Aug 28. PubMed 24074484 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2009
First posted
Apr 6, 2009
Start
Mar 2009
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Feb 10, 2014
Last update
Feb 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00876343
Responsible party
Sponsor
First posted
Apr 6, 2009
Start date
Mar 2009
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Feb 10, 2014
Last update
Feb 10, 2014

Study contacts

Katsuhisa Saito
study director · OPC-J

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion